ClinicalTrials.gg

Program

SIM0811

A development code. Also written as “SIM0811 Dose Level A (Phase II)”, “SIM0811 Dose Level B (Phase II)” and “SIM0811 Dose Level C (Phase II)”.

Its studies are mostly in Ischemic Stroke, led by Simcere Pharmaceutical Group.

Furthest: phase 3, since Oct 23, 20262 company-led studies, 1 open or runningNext primary completion: Jun 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group21 open or runningphase 3since Oct 23, 2026Dec 26, 2025Jun 30, 2029phase 3 · NCT07903701

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 26, 2025First study: phase 1 study in Health, SubjectiveFirst studyNCT07345364 · 64 enrolled · China
  2. Oct 23, 2026Phase 3 study in Acute Ischemic Stroke AISPhase 3 reachedNCT07903701 · 1,092 planned

Ahead

  1. Jun 30, 2029Primary completion: phase 3 study in Acute Ischemic Stroke AISNCT07903701

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903701Acute Ischemic Stroke AIS3Not yet recruitingJun 30, 20291,092
NCT07345364Health, Subjective · China1CompletedJun 18, 202664

How it is read

Names in the registry

  • “SIM0811 Dose Level A (Phase II)”, 1 entry
  • “SIM0811 Dose Level B (Phase II)”, 1 entry
  • “SIM0811 Dose Level C (Phase II)”, 1 entry
  • “SIM0811(Phase III)”, 1 entry
  • “SIM0811”, 1 entry

Codes read as this program: SIM0811.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.